RE:RE:RE:RE: We are pleased to report that the study is progressing well No offense, but I disagree with your statement "people privy to results"
At best there might be a handful of people who have seen the scope and seen some have ulcers developing and some do not.
They would have no way of knowing which group they are in.
Now if they are seeing roughly 50% of the subjects are healthy while roughly 50% of the subjects are having some irratation in the GI track then yes I agree with you some people might have that information but that would be limited to very small number of people working at topstone, thats it.
I suspect any shares bought from leakage of that information would be considered insider trading even thoguh they wouldn't know which group the people would belong to.
I don't think this would be an impact on share price based on how the study is going so far.
At best, the fat that people have gone through the 14 day trial and the study hasn't been stopped due to a negatiave side effect, that would be the single most important factor thus far.
Keep in mind, this is only my opinion. Do your own DD.
-Jeff